The Spectranetics Corporation (SPNC) : The consensus price target for The Spectranetics Corporation (SPNC) is $26.46 for the short term with a standard deviation of $2.91. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $30, however, the pessimist price target for the company is $22.
The Spectranetics Corporation (SPNC) : 7 brokerage houses believe that The Spectranetics Corporation (SPNC) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on The Spectranetics Corporation (SPNC). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 10 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.5.
Also, Major Brokerage house, UBS upgrades its ratings on The Spectranetics Corporation (NASDAQ:SPNC). In the latest research report, UBS raises the target price from $10 per share to $30 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. Previously, the analysts had a Sell rating on the shares. The rating by the firm was issued on August 3, 2016.
The Spectranetics Corporation (NASDAQ:SPNC): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $24.57 and $24.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.81. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.69, notching a gain of 0.33% for the day. The total traded volume was 294,109 . The stock had closed at $24.61 on the previous day.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Companys products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Companys Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.